Medical

Addicted pancreatic cancer cells die when denied key protein

Addicted pancreatic cancer cel...
By targeting vulnerabilities in pancreatic cancer cells, scientists hope to develop new forms of treatment for the disease
By targeting vulnerabilities in pancreatic cancer cells, scientists hope to develop new forms of treatment for the disease
View 1 Image
By targeting vulnerabilities in pancreatic cancer cells, scientists hope to develop new forms of treatment for the disease
1/1
By targeting vulnerabilities in pancreatic cancer cells, scientists hope to develop new forms of treatment for the disease

By better understanding the way cancer cells are able to thrive in the human body, scientists continue to learn where their vulnerabilities lie, and with that comes potential new forms of treatment. Researchers in Canada taking this approach have made a significant discovery around pancreatic cancer, pinpointing a protein the cells rely on for growth and targeting it to inhibit tumor growth in the lab.

Led by scientists at Princess Margaret Cancer Centre, the study focuses on the unique biology of pancreatic cancer cells, which drive a particularly deadly form of the disease with a five-year survival rate of just eight percent. The scientists knew that these cancer cells increase levels of a key metabolite called NADPH that helps fuel their growth, so they carried out genomic analysis to shed more light on the process.

This revealed that the cells with high levels of NADPH and undergoing uncontrolled growth as a result also suffered from oxidative stress, but an antioxidant protein called PRDX4 was able to combat these effects and enable the cells to survive. In this sense, the cancer cells are highly dependent on, or "addicted to", the protein, something the scientists hoped to leverage for their purposes.

Next, the scientists demonstrated that by targeting the PRDX4 protein in patient-derived pancreatic cancer cells, they could cause a toxic accumulation of oxidative stress that led to DNA damage and cell death. Ultimately, this technique was able to impair tumor growth in preclinical models and, importantly, left normal healthy cells unharmed.

"It's not hard to kill cancer cells," says Dr. Marianne Koritzinsky, who led the study. "It's hard to kill cancer cells without harming the cancer patient."

In this way, drugs developed to specifically target the PRDX4 protein could prove a massive boost to treatments for pancreatic cancer. These would need to be first tested in the lab and then undergo clinical trials, but Koritzinsky is now looking to explore these possibilities. Alternatively, targeting PRDX4 could be combined with other techniques such as radiotherapy to gain the upper hand on cancer cells and improve the effectiveness of the treatment.

The research was published in the journal Science Advances.

Source: Princess Margaret Cancer Centre

No comments
0 comments
There are no comments. Be the first!